JP7449092B2 - 血液脳関門移動化合物及びその使用 - Google Patents

血液脳関門移動化合物及びその使用 Download PDF

Info

Publication number
JP7449092B2
JP7449092B2 JP2019541280A JP2019541280A JP7449092B2 JP 7449092 B2 JP7449092 B2 JP 7449092B2 JP 2019541280 A JP2019541280 A JP 2019541280A JP 2019541280 A JP2019541280 A JP 2019541280A JP 7449092 B2 JP7449092 B2 JP 7449092B2
Authority
JP
Japan
Prior art keywords
seq
abp
fragment
sequence
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019541280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505926A (ja
Inventor
チャクラバーシー，バル
スタニミロヴィック，ダニカ
ドローチャー，イブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council Canada
Original Assignee
National Research Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council Canada filed Critical National Research Council Canada
Publication of JP2020505926A publication Critical patent/JP2020505926A/ja
Priority to JP2024031648A priority Critical patent/JP2024081644A/ja
Application granted granted Critical
Publication of JP7449092B2 publication Critical patent/JP7449092B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019541280A 2017-01-30 2018-01-30 血液脳関門移動化合物及びその使用 Active JP7449092B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024031648A JP2024081644A (ja) 2017-01-30 2024-03-01 血液脳関門移動化合物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762452015P 2017-01-30 2017-01-30
US62/452,015 2017-01-30
US201762530980P 2017-07-11 2017-07-11
US62/530,980 2017-07-11
PCT/IB2018/050576 WO2018138709A1 (en) 2017-01-30 2018-01-30 Blood-brain barrier transmigrating compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024031648A Division JP2024081644A (ja) 2017-01-30 2024-03-01 血液脳関門移動化合物及びその使用

Publications (2)

Publication Number Publication Date
JP2020505926A JP2020505926A (ja) 2020-02-27
JP7449092B2 true JP7449092B2 (ja) 2024-03-13

Family

ID=62977950

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019541280A Active JP7449092B2 (ja) 2017-01-30 2018-01-30 血液脳関門移動化合物及びその使用
JP2020561952A Active JP7458327B2 (ja) 2017-01-30 2018-07-31 血液脳関門移動化合物及びその使用
JP2023094278A Pending JP2023123535A (ja) 2017-01-30 2023-06-07 血液脳関門移動化合物及びその使用
JP2024031648A Pending JP2024081644A (ja) 2017-01-30 2024-03-01 血液脳関門移動化合物及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020561952A Active JP7458327B2 (ja) 2017-01-30 2018-07-31 血液脳関門移動化合物及びその使用
JP2023094278A Pending JP2023123535A (ja) 2017-01-30 2023-06-07 血液脳関門移動化合物及びその使用
JP2024031648A Pending JP2024081644A (ja) 2017-01-30 2024-03-01 血液脳関門移動化合物及びその使用

Country Status (8)

Country Link
US (3) US11702466B2 (enExample)
EP (2) EP3574002A4 (enExample)
JP (4) JP7449092B2 (enExample)
KR (3) KR102676279B1 (enExample)
CN (2) CN110382522B (enExample)
AU (4) AU2018212860A1 (enExample)
CA (2) CA3052058A1 (enExample)
WO (2) WO2018138709A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7449092B2 (ja) 2017-01-30 2024-03-13 ナショナル リサーチ カウンシル オブ カナダ 血液脳関門移動化合物及びその使用
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
MA54070A (fr) * 2018-10-29 2021-09-08 Biogen Ma Inc Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
WO2021097360A1 (en) 2019-11-15 2021-05-20 University Of Tennessee Research Foundation Modified immunoglobulins for targeting amyloid deposits
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US20240216556A1 (en) * 2021-05-05 2024-07-04 University Of Tennessee Research Foundation Peptide-fc fusions for treating amyloid disorders
WO2022246433A1 (en) 2021-05-18 2022-11-24 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders
KR102475326B1 (ko) * 2022-01-27 2022-12-07 한국기초과학지원연구원 신규한 펩타이드 유사체 및 이를 포함하는 알츠하이머 병 예방 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300141A1 (en) 2005-06-17 2011-12-08 Balu Chakravarthy Novel Alphabeta-Binding protein and its peptide derivatives and uses thereof
JP2015509097A (ja) 2012-01-10 2015-03-26 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血液脳関門を越える治療分子の輸送の向上
JP2015528452A (ja) 2012-08-29 2015-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 血液脳関門シャトル
WO2017037634A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-β-receptor ectodomain fusion molecules and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5874239A (en) 1993-07-30 1999-02-23 Affymax Technologies N.V. Biotinylation of proteins
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US20030190598A1 (en) * 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
CA2441903C (en) * 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
AU2002304814A1 (en) 2001-03-14 2002-11-05 Hybrigenics Protein-protein interactions in adipocytes
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
CA2468583C (en) 2001-11-30 2012-05-01 C. Roger Mackenzie Self-assembling multimeric binding complexes derived from ab5 toxin family members
EP1452601A1 (en) 2003-02-28 2004-09-01 Roche Diagnostics GmbH Enhanced expression of fusion polypeptides with a biotinylation tag
CA2562833A1 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
EP1943341A4 (en) 2005-09-27 2010-07-07 Ca Nat Research Council BLOOD-BRAIN-SPEED-EPITOPES AND USES THEREOF
TW200907056A (en) * 2007-03-28 2009-02-16 Astrazeneca Ab New method
EP2558503B1 (en) 2010-04-14 2015-12-09 National Research Council of Canada Compositions and methods for brain delivery of analgesic peptides
US20110269735A1 (en) * 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
ES2664989T3 (es) 2010-10-01 2018-04-24 National Research Council Of Canada Anticuerpos ANTI-CEACAM6 y usos de los mismos
EA035517B1 (ru) * 2014-03-06 2020-06-29 Нэшнл Рисеч Каунсил Оф Канада Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
JP6541237B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
EP3114142B1 (en) * 2014-03-06 2019-06-05 National Research Council of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
EP3233922B1 (en) 2014-12-19 2022-05-11 MedImmune Limited Blood brain barrier transport molecules and uses thereof
MX389765B (es) * 2016-07-06 2025-03-20 Nat Res Council Canada Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
US10906973B2 (en) * 2016-12-12 2021-02-02 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
JP7449092B2 (ja) 2017-01-30 2024-03-13 ナショナル リサーチ カウンシル オブ カナダ 血液脳関門移動化合物及びその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300141A1 (en) 2005-06-17 2011-12-08 Balu Chakravarthy Novel Alphabeta-Binding protein and its peptide derivatives and uses thereof
JP2015509097A (ja) 2012-01-10 2015-03-26 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血液脳関門を越える治療分子の輸送の向上
JP2015528452A (ja) 2012-08-29 2015-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 血液脳関門シャトル
WO2017037634A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-β-receptor ectodomain fusion molecules and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular Pharmaceutics，2013年08月07日，Vol.10，pp.3507-3513

Also Published As

Publication number Publication date
WO2019150183A1 (en) 2019-08-08
CN111886240A (zh) 2020-11-03
KR102676279B1 (ko) 2024-06-20
AU2022202015B2 (en) 2023-12-21
CA3089816A1 (en) 2019-08-08
EP3574002A1 (en) 2019-12-04
US20190352383A1 (en) 2019-11-21
AU2018212860A1 (en) 2019-08-15
EP3574002A4 (en) 2021-04-21
AU2024201813A1 (en) 2024-04-11
AU2018405992A1 (en) 2020-08-20
WO2018138709A1 (en) 2018-08-02
JP2024081644A (ja) 2024-06-18
JP2021512159A (ja) 2021-05-13
AU2022202015A1 (en) 2022-04-14
US20230257424A1 (en) 2023-08-17
CN110382522A (zh) 2019-10-25
CN110382522B (zh) 2024-08-30
EP3746460A4 (en) 2022-04-20
JP2020505926A (ja) 2020-02-27
JP7458327B2 (ja) 2024-03-29
KR20240095466A (ko) 2024-06-25
KR20200116143A (ko) 2020-10-08
US11702466B2 (en) 2023-07-18
KR20190112768A (ko) 2019-10-07
US20230279088A1 (en) 2023-09-07
CA3052058A1 (en) 2018-08-02
JP2023123535A (ja) 2023-09-05
EP3746460A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
JP7458327B2 (ja) 血液脳関門移動化合物及びその使用
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
JP6541237B2 (ja) インスリン様成長因子１受容体特異的抗体及びそれらの使用
AU2018312441B2 (en) Antibody binding active alpha-synuclein
TW201103560A (en) Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EA035517B1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
JP2022509372A (ja) 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント
HK40022840B (en) ANTIBODIES TO α‐SYNUCLEIN AND USES THEREOF
HK1166331B (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20190927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240301

R150 Certificate of patent or registration of utility model

Ref document number: 7449092

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150